Seeing Is Believing
Currently out of the existing stock ratings of Edward Nash, 156 are a BUY (90.7%), 14 are a HOLD (8.14%), 2 are a SELL (1.16%).
Analyst Edward Nash, currently employed at CANACCORD, carries an average stock price target met ratio of 43.1% that have a potential upside of 37.65% achieved within 206 days.
Edward Nash’s has documented 338 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TVTX, Travere Therapeutics at 10-Apr-2025.
Analyst best performing recommendations are on BLUE (BLUEBIRD BIO).
The best stock recommendation documented was for BLUE (BLUEBIRD BIO) at 6/6/2017. The price target of $69.95 was fulfilled within 1 day with a profit of $6.38 (10.04%) receiving and performance score of 100.36.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$3
$2.89 (2627.27%)
$10
6 years 5 months 11 days ago
(13-Nov-2018)
0/5 (0%)
$1.07 (55.44%)
Buy
$3
$2.89 (2627.27%)
$22
6 years 5 months 12 days ago
(12-Nov-2018)
0/3 (0%)
$1 (50.00%)
Hold
$3
$2.89 (2627.27%)
$19
6 years 5 months 12 days ago
(12-Nov-2018)
0/5 (0%)
$1 (50.00%)
Hold
$8
6 years 5 months 15 days ago
(09-Nov-2018)
1/6 (16.67%)
$4.75 (146.15%)
40
Hold
6 years 5 months 15 days ago
(09-Nov-2018)
1/4 (25%)
$8.57 (47.07%)
31
Which stock is Edward Nash is most bullish on?
Which stock is Edward Nash is most reserved on?
What Year was the first public recommendation made by Edward Nash?